Skip to main content
Do you know your risk?

Understanding your risk of breast cancer coming back is the first step


Everyone's journey with breast cancer is unique. We are here to help you better understand what you can do to help prevent your cancer coming back.

If you are one of the many women who experienced the most common type of early breast cancer, HR+, HER2-, you may still be at risk of cancer coming back even after surgery, radiation, and/or chemotherapy.

Even women who received hormone therapy after these initial treatments were at risk of cancer coming back within 20 years. The odds of recurrence are:

1 in 3 people with no cancer in their lymph nodes. 1 in 2 people with cancer in ≥ 4 lymph nodes.

The risk is real, but you have options. Learn about a treatment that can help patients like you.

HR+, hormone receptor-positive; HER2-, human epidermal growth factor receptor 2-negative.

Get access to helpful resources

* Required fields

Are you looking for information for yourself or a loved one?

By clicking SUBMIT, you represent that you are 18 years of age or older and agree to the Novartis Pharmaceuticals Corporation (NPC) Terms of Use. You understand and agree that the information you provide will be used in accordance with the NPC Privacy Policy, and to provide you with marketing information, offers, and promotions, and to contact you for your opinions regarding products, programs, and services. NPC may also show you relevant health-related advertisements when you visit other websites. To learn about our interest-based ads, click hereYou understand that unless you unsubscribe, by calling 1-888-669-6682 or clicking unsubscribe in a promotional email, your consent will remain valid.

Get helpful information and connect with support groups on their websites*:
*This is not an exclusive list of organizations. All of these organizations are not-for-profit, and are independent from Novartis Pharmaceuticals Corporation. Novartis has no financial interest in any organization listed, but may provide occasional funding support to these organizations. All trademarks referenced are the property of their respective owners.